Lymphoma, B-Cell

Oncology
12
Pipeline Programs
11
Companies
25
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
3100%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
2 programs
1
1
inotuzumab ozogamicinPhase 2ADC
inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisonePhase 1ADC
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
Adenovirus Interferon gammaPhase 21 trial
Active Trials
NCT00394693CompletedEst. Apr 2010
E
EisaiChina - Liaoning
1 program
1
ONTAKPhase 21 trial
Active Trials
NCT00211276Completed50Est. Feb 2007
DS
Daiichi SankyoChina - Shanghai
1 program
1
Valemetostat tosylatePhase 21 trial
Active Trials
NCT04842877Active Not Recruiting141Est. Oct 2026
Fate Therapeutics
Fate TherapeuticsSAN DIEGO, CA
2 programs
2
FT596Phase 11 trial
FT819Phase 11 trial
Active Trials
NCT04245722TerminatedEst. Sep 2023
NCT04629729Active Not RecruitingEst. Sep 2039
Eureka Therapeutics
Eureka TherapeuticsCA - Emeryville
1 program
1
ET190L1 ARTEMIS™ T cellsPhase 11 trial
Active Trials
NCT03415399CompletedEst. Dec 2020
Pfizer
PfizerNEW YORK, NY
1 program
1
Inotuzumab OzogamicinPhase 1ADC5 trials
Active Trials
NCT03127605Approved For Marketing
NCT05748171Recruiting100Est. Nov 2036
NCT05597085Completed32Est. Jul 2023
+2 more trials
Umoja Biopharma
Umoja BiopharmaWA - Seattle
1 program
1
UB-VV111Phase 11 trial
Active Trials
NCT06528301Recruiting106Est. Mar 2029
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
VenetoclaxPhase 1
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
VenetoclaxPhase 11 trial
Active Trials
NCT04161248Recruiting18Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
Daiichi SankyoValemetostat tosylate
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
PfizerInotuzumab Ozogamicin
TransgeneAdenovirus Interferon gamma
EisaiONTAK
Umoja BiopharmaUB-VV111
PfizerInotuzumab Ozogamicin
Fate TherapeuticsFT819

Showing 15 of 24 trials with date data

Clinical Trials (25)

Total enrollment: 1,675 patients across 25 trials

NCT05687032PfizerInotuzumab Ozogamicin

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Start: Feb 2023Est. completion: Nov 202544 patients
Phase 4Completed
NCT01564784PfizerInotuzumab Ozogamicin

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Start: Aug 2012Est. completion: Jan 2017326 patients
Phase 3Completed
NCT01232556PfizerInotuzumab Ozogamicin

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Start: Apr 2011Est. completion: Mar 2014338 patients
Phase 3Terminated
NCT00562965PfizerInotuzumab Ozogamicin

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Start: Nov 2007Est. completion: Apr 201129 patients
Phase 3Terminated
NCT05748171PfizerInotuzumab Ozogamicin

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Start: May 2023Est. completion: Nov 2036100 patients
Phase 2Recruiting
NCT04842877Daiichi SankyoValemetostat tosylate

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Start: Jun 2021Est. completion: Oct 2026141 patients
Phase 2Active Not Recruiting
NCT03913559PfizerInotuzumab Ozogamicin

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Start: May 2019Est. completion: Sep 20255 patients
Phase 2Terminated
NCT01363297PfizerInotuzumab Ozogamicin

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Start: Aug 2011Est. completion: Jan 201672 patients
Phase 2Completed
NCT00868608PfizerInotuzumab Ozogamicin

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Start: Jul 2009Est. completion: Jun 201381 patients
Phase 2Completed
NCT00867087PfizerInotuzumab Ozogamicin

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Start: Jun 2009Est. completion: Oct 201264 patients
Phase 2Completed
NCT00394693TransgeneAdenovirus Interferon gamma

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Start: Nov 2006Est. completion: Apr 2010
Phase 2Completed
NCT00211276EisaiONTAK

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Start: Mar 2005Est. completion: Feb 200750 patients
Phase 2Completed
NCT06528301Umoja BiopharmaUB-VV111

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Start: Mar 2025Est. completion: Mar 2029106 patients
Phase 1Recruiting
NCT03962465PfizerInotuzumab Ozogamicin

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Start: Jul 2022Est. completion: Jul 202636 patients
Phase 1Active Not Recruiting
NCT04629729Fate TherapeuticsFT819

FT819 in Subjects With B-cell Malignancies

Start: Jul 2021Est. completion: Sep 2039
Phase 1Active Not Recruiting
NCT04161248AbbVieVenetoclax

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Start: Sep 2020Est. completion: Dec 202618 patients
Phase 1Recruiting
NCT04245722Fate TherapeuticsFT596

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Start: Mar 2020Est. completion: Sep 2023
Phase 1Terminated
NCT03415399Eureka TherapeuticsET190L1 ARTEMIS™ T cells

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Start: Sep 2017Est. completion: Dec 2020
Phase 1Completed
NCT01055496PfizerInotuzumab Ozogamicin

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Start: Mar 2010Est. completion: Mar 2014103 patients
Phase 1Completed
NCT00724971PfizerInotuzumab Ozogamicin

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Start: Jul 2008Est. completion: Mar 201010 patients
Phase 1Completed
NCT00717925PfizerInotuzumab Ozogamicin

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

Start: Mar 2007Est. completion: Jul 200813 patients
Phase 1Completed
NCT00073749PfizerInotuzumab Ozogamicin

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Start: Aug 2003Est. completion: Dec 201079 patients
Phase 1Completed
NCT03127605PfizerInotuzumab Ozogamicin

Inotuzumab Ozogamicin - PF-05208773

N/AApproved For Marketing
NCT05597085PfizerInotuzumab Ozogamicin

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Start: Mar 2023Est. completion: Jul 202332 patients
N/ACompleted
NCT04456959PfizerInotuzumab Ozogamicin

InO - A Retrospective Study of UK Patients With Leukaemia

Start: Jan 2020Est. completion: Jan 202128 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,675 patients
11 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)